Equities Analysts Set Expectations for Lexeo Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:LXEO)

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Research analysts at Leerink Partnrs issued their FY2027 earnings estimates for shares of Lexeo Therapeutics in a note issued to investors on Tuesday, April 23rd. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings per share of ($2.58) for the year. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.03) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2028 earnings at $0.12 EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15).

Lexeo Therapeutics Price Performance

Lexeo Therapeutics stock opened at $12.16 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.21. Lexeo Therapeutics has a 1-year low of $9.00 and a 1-year high of $22.33. The stock has a 50-day moving average price of $14.37.

Institutional Trading of Lexeo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blackstone Inc. purchased a new stake in Lexeo Therapeutics in the 4th quarter worth about $9,342,000. Omega Fund Management LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter worth about $28,955,000. Finally, Eventide Asset Management LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter worth about $40,298,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.